COMMUNIQUÉS West-GlobeNewswire

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
16/12/2025
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the University Health Network Research Ethics Board (“UHN REB”) has [...]
Marine Biologics Named a Top Food Technology Company for 2025 in Global Food Tech Awards
16/12/2025
Innovator building the AI for clean-label ingredient discovery is recognized as a global game-changing technology shaping the future of food BERKELEY, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Marine Biologics today [...]
Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America
16/12/2025
Role Supports Synergy’s Expanding Presence in Mexico, Including Initial Product Shipments to Costco Mexico WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company [...]
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
16/12/2025
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolment Strong operational progress continues globally with over 120 activated clinical sites and 27 [...]
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
16/12/2025
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is [...]
Elicio Therapeutics Reports Inducement Grants
16/12/2025
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Annovis to Host Corporate Update Webinar on January 28, 2026
16/12/2025
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
16/12/2025
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
Jushi Holdings Inc. Announces Amendment to CEO Employment Agreement
16/12/2025
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“ Jushi ” or the “ Company ”) (CSE: JUSH ) ( OTCQX: JUSHF ), a vertically integrated, multi-state cannabis operator, announces that in order to [...]
Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
16/12/2025
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterally LONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the [...]
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
16/12/2025
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
16/12/2025
MediBeacon ® TGFR™ System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers begins in early 2026 ST. LOUIS, Dec. 16, 2025 [...]
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
16/12/2025
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has [...]
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
16/12/2025
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and dermatitis Efficacy comparable to [...]
Starton Therapeutics to Present at Biotech Showcase 2026
16/12/2025
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in San Francisco PARAMUS, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“ [...]
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
16/12/2025
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a [...]
Nova Leap Health Corp. Launches Care Management Division In the United States
16/12/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
16/12/2025
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted [...]
Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease
16/12/2025
Approval of Elfabrio® provides an additional treatment option for those living with Fabry disease PARMA, Italy and WOODBRIDGE, Ontario, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of [...]

Pages